Evidence map›Paper›PMID 34889260›Full record

ArticleMedicine2021

Hepatitis C infection and chronic kidney disease among Hispanics/Latinos.

Eugenia Wong, Ana C Ricardo, Sylvia E Rosas, James P Lash, Nora Franceschini

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Eugenia WongDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-1263-9755
Ana C RicardoDepartment of Medicine, University of Illinois at Chicago, Chicago, IL.
Sylvia E RosasJoslin Diabetes Center and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
James P LashDepartment of Medicine, University of Illinois at Chicago, Chicago, IL.
Nora FranceschiniDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Apple (Israel) · ILUniversity of North Carolina at Chapel Hill · USJoslin Diabetes Center · US

Funding

Health Disparities in Chronic Kidney Disease Mentoring ProgramK24DK092290 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LASH, JAMES P. · 2012 to 2022
$1.9M
NHGRI NIH HHS HHSN268201300003CNHLBI NIH HHS HHSN268201300001CNHLBI NIH HHS HHSN268201300001INHLBI NIH HHS HHSN268201300002INHLBI NIH HHS HHSN268201300003INHLBI NIH HHS HHSN268201300004CNHLBI NIH HHS HHSN268201300004INHLBI NIH HHS HHSN268201300005CNHLBI NIH HHS HHSN268201300005INIDDK NIH HHS K24 DK092290NIDDK NIH HHS K24-DK092290
6 · The paper itself

Abstract

abstractViral infections, including hepatitis C, can cause secondary glomerular nephropathies. Studies suggest that hepatitis C virus infection (HCV+) is a risk factor for chronic kidney disease (CKD) but evidence of this relationship is lacking among Hispanics/Latinos. We examined the association between HCV+ and incident CKD in a prospective cohort of Hispanics/Latinos enrolled in the Hispanic Community Health Study/Study of Latinos. HCV+ was defined by detectable HCV antibodies with additional confirmation through HCV RNA or recombinant immunoblot assay testing. Incident CKD was defined by an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or sex-specific threshold for albuminuria measured during follow-up. We used Poisson regression to estimate incidence rate ratios (IRR) of CKD and changes in eGFR- or albuminuria-based risk stages, separately. We used linear regression to estimate associations with continuous, annualized changes in eGFR and albuminuria.Over a follow-up period of 5.9 years, 712 incident CKD events occurred among 10,430 participants. After adjustment for demographic characteristics and comorbidities, HCV+ was not associated with incident CKD, defined by eGFR and albuminuria thresholds (IRR 1.29, 95% Confidence Interval 0.61, 2.73). HCV+ was significantly associated with higher eGFR risk stages (IRR 2.39, 95% CI 1.47, 3.61) with most participants transitioning from stage G1 to G2. HCV+ was associated with a continuous, annualized eGFR decline of -0.69 mL/min/m2/year (95% CI -1.23, -0.16). This large, cohort study did not find evidence of a strong association between HCV+ and new-onset CKD among Hispanics/Latinos. HCV infection may not be associated with risk of CKD among Hispanics/Latinos, although treatment with direct-acting antivirals is recommended for all HCV+ individuals, including those with established CKD or end-stage kidney disease.

Indexed as

AlbuminuriaAntiviral AgentsFemaleGlomerular Filtration RateHepacivirusHepatitis C, ChronicHispanic or LatinoHumansMaleProspective StudiesRenal Insufficiency, ChronicRisk FactorsAntiviral Agents

Identifiers

PMID34889260
PMCPMC8663903
OpenAlexW4200249607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.